Trial · NCT00558103
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomized Treatment Phase | STARTED | Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo | 38 | |
| Randomized Treatment Phase | STARTED | Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg | 38 | |
| Randomized Treatment Phase | STARTED | Cohort 2: Lapatinib 1500 mg + Pazopanib Placebo | 36 | |
| Randomized Treatment Phase | STARTED | Cohort 2: Pazopanib 800 mg | 13 | |
| Randomized Treatment Phase | STARTED | Cohort 2: Lapatinib 1000 mg + Pazopanib 400 mg | 38 | |
| Randomized Treatment Phase | STARTED | Open-label Lapatinib 1500 mg | 0 | |
| Randomized Treatment Phase | COMPLETED | Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo | 33 | |
| Randomized Treatment Phase | COMPLETED | Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg | 34 | |
| Randomized Treatment Phase | COMPLETED | Cohort 2: Lapatinib 1500 mg + Pazopanib Placebo | 33 | |
| Randomized Treatment Phase | COMPLETED | Cohort 2: Pazopanib 800 mg | 11 | |
| Randomized Treatment Phase | COMPLETED | Cohort 2: Lapatinib 1000 mg + Pazopanib 400 mg | 33 | |
| Randomized Treatment Phase | COMPLETED | Open-label Lapatinib 1500 mg | 0 | |
| Randomized Treatment Phase | NOT COMPLETED | Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo | 5 | |
| Randomized Treatment Phase | NOT COMPLETED | Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg | 4 | |
| Randomized Treatment Phase | NOT COMPLETED | Cohort 2: Lapatinib 1500 mg + Pazopanib Placebo | 3 | |
| Randomized Treatment Phase | NOT COMPLETED | Cohort 2: Pazopanib 800 mg | 2 | |
| Randomized Treatment Phase | NOT COMPLETED | Cohort 2: Lapatinib 1000 mg + Pazopanib 400 mg | 5 | |
| Randomized Treatment Phase | NOT COMPLETED | Open-label Lapatinib 1500 mg | 0 | |
| Monotherapy Extension Phase | STARTED | Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo | 0 | |
| Monotherapy Extension Phase | STARTED | Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00558103/flow